Drugs / Alfentanil
Alfentanil
also known as
Afentanyl · Alf · Alfenta · alfentanil = rapifen · Alfentanil Hydrochloride · Alfentanil hydrochloride cii · Alfentanil hydrochloride monohydrate · Alfentanilo · +7 more
Other / unclassified targets OPRM1 via activation
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ALFENTA | — | 1993-11-22 | fda.gov ↗ |
| Approved | US (FDA) | ALFENTA | — | 1986-12-29 | fda.gov ↗ |
Trials 21 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07710560 | Jul 2026 overdue | chronic pain syndrome | Hunan Kelun Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07581665 | May → Aug 2026 overdue | — | Zhongshan Ophthalmic Center, Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06563297 | Aug → Dec 2024 | — | Kaohsiung Medical University Chung-Ho Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT05344911 | Apr → Jul 2022 | — | Xijing Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02358057 | Feb 2015 → Apr 2016 | — | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| Phase 4 | NCT02267681 | Oct 2014 → May 2016 | delirium, digestive system disorder | Perihan Ekmekçi | Completed | No outcome recorded |
| Phase 4 | NCT01470170 | Oct 2010 → Sep 2011 | — | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01518608 | Sep 2009 → Sep 2011 | — | Oslo University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00742807 | Aug 2008 → May 2015 | — | University Hospital, Ghent | Withdrawn | No outcome recorded |
| Phase 4 | NCT00440960 | — | lung cancer | Hospital Pompeia | Completed | No outcome recorded |
| Phase not applicable11 trials | ||||||
| — | NCT06414018 | May → Dec 2024 | — | Tongji Hospital | Completed | No outcome recorded |
| — | NCT06026566 | Apr 2023 → Aug 2025 | — | Tongji Hospital | Unknown | No outcome recorded |
| — | NCT02646592 | Apr → Oct 2016 | — | Pr Isabelle CONSTANT | Completed | No outcome recorded |
| — | NCT04196946 | Sep 2013 → Sep 2015 | — | Nigde Omer Halisdemir University | Completed | No outcome recorded |
| — | NCT02486926 | Nov 2012 → Jul 2013 | — | Hallym University Medical Center | Completed | No outcome recorded |
| — | NCT01371968 | Feb → Aug 2011 | reactive airway disease | University of Malaya | Completed | No outcome recorded |
| — | NCT01008059 | Oct 2009 → Sep 2016 | — | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00991809 | Feb 2009 → May 2010 | — | Johns Hopkins University | Completed | No outcome recorded |
| — | NCT00672438 | May 2008 → Jun 2010 | — | Martin Angst | Completed | No outcome recorded |
| — | NCT00434382 | Oct 2002 → Dec 2003 | — | Ludwig-Maximilians - University of Munich | Unknown | No outcome recorded |
| — | NCT00226564 | Aug 1997 → ? | nephrolithiasis | Hadassah Medical Organization | Completed | No outcome recorded |
Also used as a comparator or background therapy in 25 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT01805726 Comparator | Feb → Mar 2013 | — | Saint-Joseph University | Completed | No outcome recorded |
| Phase 3 | NCT01235637 Comparator | Jun 2010 → Jun 2012 | — | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 411 trials | ||||||
| Phase 4 | NCT07347496 Background | Mar 2026 → May 2028 expected | — | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07395596 Background | Feb → Dec 2026 expected | infectious disease, lung disorder, lymphangiectasis, trachea neoplasm | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 4 | NCT05688384 Comparator | Jan 2023 → Nov 2024 | cancer | Region Jönköping County | Completed | No outcome recorded |
| Phase 4 | NCT03359395 Comparator | Jun 2018 → Feb 2020 | hypertensive disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT03521505 Comparator | May 2018 → Jan 2020 | — | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02022488 Comparator | Feb → Aug 2012 | — | Yeditepe University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01199458 Comparator | Sep → Oct 2010 | — | Region Örebro County | Completed | No outcome recorded |
| Phase 4 | NCT00997126 Comparator | Oct 2009 → Apr 2015 | — | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT00997113 Comparator | Oct 2009 → Oct 2012 | — | Hennepin Healthcare Research Institute | Completed | No outcome recorded |
| Phase 4 | NCT01350037 Comparator | Jun → Sep 2009 | biliary tract disorder, pancreas disorder | Helsinki University Central Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00789815 Comparator | Apr 2008 → Sep 2009 | — | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase not applicable12 trials | ||||||
| — | NCT07335536 Background | Oct 2025 → Dec 2026 expected | infertility disorder | Diansan Su | Recruiting | No outcome recorded |
| — | NCT07211828 Comparator | Oct 2025 → Dec 2026 expected | — | Chi Kwan Fung | Recruiting | No outcome recorded |
| — | NCT04658173 Comparator | Dec 2020 → Oct 2022 | — | Tianjin Nankai Hospital | Unknown | No outcome recorded |
| — | NCT02838056 Background | Feb → Sep 2017 | — | Taipei Medical University WanFang Hospital | Unknown | No outcome recorded |
| — | NCT02625181 Background | Jul 2016 → Nov 2017 | — | Vanderbilt University | Completed | No outcome recorded |
| — | NCT02000206 Comparator | Feb → Sep 2014 | lung disorder | Rabin Medical Center | Unknown | No outcome recorded |
| — | NCT01550354 Comparator | Feb 2012 → Jan 2014 | ankyloglossia | Yonsei University | Completed | No outcome recorded |
| — | NCT01436799 Background | Mar → Aug 2011 | brain ischemia | Gachon University Gil Medical Center | Completed | No outcome recorded |
| — | NCT01049672 Comparator | Sep 2010 → Nov 2014 | cancer | Gloucestershire Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| — | NCT01289327 Comparator | Apr → Nov 2010 | lung disorder | Rabin Medical Center | Completed | No outcome recorded |
| — | NCT01094574 Comparator | Jan → Jun 2010 | — | Martin Angst | Completed | No outcome recorded |
| — | NCT00566683 Comparator | Jul 2005 → Jun 2006 | — | North District Hospital | Completed | No outcome recorded |
Evidence & citations 20 cited values
Every value below carries the sentence it was read from. 47 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alfentanil | “As an important member of opioid receptor agonist, 30s of alfentanil exerts its drug effect, and its safety is far better than that of morphine.” NCT06026566 ↗44“5 mg/kg alfentanil (1:10 dilution) slow injection 2 min before complete Dexmedetomidine induction” NCT03521505 ↗ “2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate” NCT02838056 ↗ “Alfentanil: 5μg/kg slowly push” NCT00789815 ↗ |
| Known as | Afentanyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Alf | “Alfentanil (Alf) is used in combination with Propofol (Pro) in fiber-bronchoscopy and in many other conscious sedation procedures.” NCT01470170 ↗ |
| Known as | Alfenta | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | alfentanil = rapifen | “alfentanil = rapifen” NCT01199458 ↗ |
| Known as | Alfentanil Hydrochloride | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07710560 ↗ |
| Known as | Alfentanil hydrochloride cii | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Alfentanil hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Alfentanilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Alfentanyl | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | IDS-NA-014 | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | R 39,209 | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Rapifen | “Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)” NCT01518608 ↗ |
| Known as | Rapifen conc | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Rapifen dilute | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Known as | Rapifen intensive care | ChEMBL registry synonym — accepted as the source's own label CHEMBL634 ↗ |
| Action | Activate | “Mu opioid receptor agonist” CHEMBL634 ↗1“It is an OP3 mu-agonist.” NCT01350037 ↗ |
| Modality | Other / unclassified | “synthetic opioid analgesic drug” NCT01350037 ↗ |
| Route | Intravenous | “Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml” NCT00672438 ↗ |
| Target | OPRM1 | “Mu opioid receptor agonist” CHEMBL634 ↗ |